A Phase One, Open Label, Multi-Dose Study To Evaluate The Safety, Tolerability, And Biologic Effects Of Three Doses Of Iw001 In Patients With Idiopathic Pulmonary Fibrosis (ipf)

被引：0
|
作者：
Rothhaar, K. [1 ]
Chew, T. [1 ]
Frye, S. [1 ]
Klemsz, M. [2 ]
Lange, W. [1 ]
Wilkes, D. S. [2 ]
机构：
[1] ImmuneWorks Inc, Indianapolis, IN USA
[2] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5709
引用
收藏
页数：1
相关论文
共 44 条
  • [31] Macrophage Therapy for Acute Liver Injury (MAIL): a study protocol for a phase 1 randomised, open-label, dose-escalation study to evaluate safety, tolerability and activity of allogeneic alternatively activated macrophages in patients with paracetamol-induced acute liver injury in the UK
    Humphries, Christopher
    Addison, Melisande
    Aithal, Guruprasad
    Boyd, Julia
    Briody, Lesley
    Campbell, John D. M.
    Candela, Maria Elena
    Clarke, Ellise
    Coulson, James
    Downing-James, Nicholas
    Fontana, Robert John
    Geddes, Ailsa
    Grahamslaw, Julia
    Grant, Alison
    Heye, Anna
    Hutchinson, James A.
    Jones, Ashley
    Mitchell, Fiona
    Moore, Joanna
    Riddell, Alice
    Rodriguez, Aryelly
    Thomas, Angela
    Tucker, Garry
    Walker, Kim
    Weir, Christopher J.
    Woods, Rachel
    Zahra, Sharon
    Forbes, Stuart J.
    Dear, James W.
    BMJ OPEN, 2024, 14 (12):
  • [32] A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors
    Huang, Zhiyu
    Xu, Yanjun
    Hong, Wei
    Gong, Lei
    Chen, Kaiyan
    Qin, Jing
    Xie, Fajun
    Wang, Feng
    Tian, Xin
    Meng, Xiangrui
    Feng, Wenlei
    Li, Lingyan
    Zhang, Baihui
    Kang, Xiaoyan
    Fan, Yun
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [33] An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
    Dudek, M. A.
    Zaslona, Z.
    Blaszczyk, R.
    Grzybowski, M. M.
    Rejczak, T.
    Cabaj, A.
    Dera, P.
    Lisiecki, K.
    Iwanowski, P.
    Charitos, T.
    Fung, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S495 - S495
  • [34] A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos (t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B-Interim results of the OCTOPUS-1 study
    Asselah, Tarik
    Fung, Scott K.
    Akhan, Sila
    Chuang, Wan-Long
    Buti, Maria
    Brunetto, Maurizia
    Agarwal, Kosh
    Diba, Camellia
    Jerzorwski, John
    Kakuda, Thomas
    Nalpas, Catherine
    Guinard-Azadian, Carine
    Verbinnen, Thierry
    Lathouwers, Erkki
    De Creus, An
    Lenz, Oliver
    Biermer, Michael
    JOURNAL OF HEPATOLOGY, 2024, 80 : S27 - S28
  • [35] Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma
    Lust, John A.
    Barranco, Charles
    Usmani, Saad Z.
    van Rhee, Frits
    Hamadani, Mehdi
    Thompson, John
    Taylor, Catherine A.
    Dondero, Richard
    Browne, Leslie J.
    Siegel, David
    Bensinger, William I.
    BLOOD, 2013, 122 (21)
  • [36] A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema
    Brigell, Mitchell G.
    Campochiaro, Peter A.
    Sophie, Raafay
    Tolentino, Michael
    Miller, Daniel
    Browning, David
    Boyer, David S.
    Heier, Jeffrey S.
    Peters, Kevin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [37] An Open-Label, Dose-Escalation, Phase 1a Study to Evaluate Safety, Tolerability, and Exploratory Efficacy of Intravenous Injection of Allogenic Early-Passage Mesenchymal Stem Cells (MSCs), Derived from Wharton's Jelly in the Umbilical Cord, in Patients with Duchenne Muscular Dystrophy
    Lee, Jeehun
    MOLECULAR THERAPY, 2023, 31 (04) : 462 - 462
  • [38] A PHASE 1A/1B, MULTI-CENTER, OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF THE PLEIOTROPIC PATHWAY MODIFIER CC-122 ADMINISTERED ORALLY TO PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) AND OTHER BRAIN TUMORS
    Simonelli, Matteo
    Sepulveda, Juan
    Brandes, Alba
    Soria, Jean-Charles
    Edenfield, John
    Moreno, Victor
    Perez-Larraya, Jaime Gallego
    Britten, Carolyn
    Cloughesy, Timothy F.
    Matinez Garcia, Maria
    Balana, Carme
    Hagner, Patrick
    Li, Yan
    Wei, Xin
    Gandhi, Anita
    Pourdehnad, Michael
    Lopez Martin, Jose Antonio
    Santoro, Armando
    Shih, Kent
    NEURO-ONCOLOGY, 2016, 18 : 24 - 24
  • [39] A Phase 2 Placebo-Controlled, Randomized, Double-Blind Clinical Study To Assess The Efficacy, Safety And Tolerability Of Two Doses Of Pulsed, Inhaled Nitric Oxide (ino) In Patients With Who Group 1 Pulmonary Arterial Hypertension (pah): 12 Month Interim Analysis Of Open Label Extension
    Benza, R. L.
    Barst, R.
    Granton, J.
    Badesch, D.
    Frost, A.
    Farber, H.
    Hirani, N.
    Hill, W.
    Shapiro, S.
    Quinn, D.
    Fleming, T.
    Elliott, C. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [40] MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors
    Baird, Richard
    Omlin, Aurelius
    Kiemle-Kallee, Joachim
    Fiedler, Ulrike
    Zitt, Christof
    Feurstein, Daniel
    Herbst, Joerg
    Dawson, Keith
    vom Baur, Elmar
    Stumpp, Michael
    Hermann, Frank
    Harstrick, Andreas
    Schneeweiss, Andreas
    CANCER RESEARCH, 2018, 78 (04)
12345